OBSV News and Press, ObsEva SA From 09/29/19

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive...

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s rep...

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva’s novel oxytocin receptor antagonist nolasiban Geneva,...

ObsEva SA (OBSV) Q2 2019 Earnings Conference Call August 7, 2019 08:00 ET Company Participants Mario Corso - Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer and Head, R&D Wim Souverijns - Chief Comm...

Geneva, Switzerland and Boston, MA – August 9, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...

ObsEva (NASDAQ: OBSV ): Q2 GAAP EPS of -$0.80 misses by $0.21 . Press Release More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news,

  Multiple Major Milestones Expected This Year -    Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban   -    Nolasiban MAA submission targeted for year- end 2019 -    Q4:19 Phase 3 data for PRIMROSE 2 trial of linzagolix in uterine fibroids ...

  Geneva, Switzerland and Boston, MA – August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s repro...